Influence of different CLA isomers on insulin resistance and adipocytokines in pre-diabetic, middle-aged men with PPARc2 Pro12Ala polymorphism

Genes and Nutrition

Volumn 7, Issue 4, 2012, Pages 499-509

  Rubin, Diana ^a,b   Herrmann, Julia ^a   Much, Daniela ^c   Pfeuffer, Maria ^a   Laue, C ^d   Winkler, P ^d   Helwig, Ulf ^a   Bell, Doris ^e   Auinger, Annegret ^a   Darabaneanu, Stephanie ^d   Ruether, Andreas ^f   Schrezenmeir, Jurgen ^a  

^a FEDERAL RESEARCH INSTITUTE OF NUTRITION AND FOOD   (Germany)

^b FEDERAL INSTITUTE FOR RISK ASSESSMENT   (Germany)

^c LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^d UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^e GERMAN AEROSPACE CENTER DLR   (Germany)

^f UNIVERSITY OF KIEL   (Germany)

Author keywords

Adipocytokines; Adiponectin; CLA; Diabetes; Gene nutrient interaction; HOMA; Insulin; Insulin resistance; Metabolic syndrome; Nutrigenetic; Postprandial; PPAR Pro12Ala; Triglycerides

Indexed keywords

ADIPOCYTOKINE; ALANINE; CONJUGATED LINOLEIC ACID; GLUCOSE; INSULIN; LEPTIN; LINOLEIC ACID; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA 2; PLACEBO; PROLINE; TONALIN; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIET RESTRICTION; DOUBLE BLIND PROCEDURE; FOOD INTAKE; GENETIC POLYMORPHISM; GENOTYPE; HETEROZYGOTE; HUMAN; IMPAIRED GLUCOSE TOLERANCE; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIPID ANALYSIS; MALE; POSTPRANDIAL STATE; RANDOMIZED CONTROLLED TRIAL; WAIST CIRCUMFERENCE; WEIGHT GAIN;

EID: 84872200698     PISSN: 15558932     EISSN: 18653499     Source Type: Journal    
DOI: 10.1007/s12263-012-0289-3     Document Type: Article

References (34)

1. Arita Y, Kihara S, Ouchi N, Takahashi M, Maeda K, Miyagawa J, Hotta K, Shimomura I, Nakamura T, Miyaoka K, Kuriyama H, Nishida M, Yamashita S, Okubo K, Matsubara K, Muraguchi M, Ohmoto Y, Funahashi T, Matsuzawa Y (1999) Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun 257:79-83 (Pubitemid 29299050)
2. Armoni M, Kritz N, Harel C, Bar-Yoseph F, Chen H, Quon MJ, Karnieli E (2003) Peroxisome proliferator-activated receptor-{gamma} represses GLUT4 promoter activity in primary adipocytes, and rosiglitazone alleviates this effect. J Biol Chem 278:30614-30623. doi:10.1074/jbc.M304654200 (Pubitemid 36994566)
3. Belury MA, Vanden Heuvel JP (1999) Modulation of diabetes by conjugated linoleic acid. In: Yurawecz MP, Mossoba MM, Kramer JKG, Pariza MW, Nelson GJ (eds) Advances in conjugated linoleic acid research, vol 1. AOCS Press Champaign, IL, pp 404-411
4. Belury MA (2002) Inhibition of carcinogenesis by conjugated linoleic acid: Potential mechanisms of action. J Nutr 132:2995-2998
5. Belury MA, Mahon A, Banni S (2003) The conjugated linoleic acid (CLA) isomer, t10c12-CLA, is inversely associated with changes in body weight and serum leptin in subjects with type 2 diabetes mellitus. J Nutr 133:257S-260S (Pubitemid 36070613)
6. Cole SA, Mitchell BD, Hsueh WC, Pineda P, Beamer BA, Shuldiner AR, Comuzzie AG, Blangero J, Hixson JE (2000) The Pro12Ala variant of peroxisome proliferator-activated receptor-gamma2 (PPAR-gamma2) is associated with measures of obesity in Mexican Americans. Int J Obes Relat Metab Disord 24:522-524 (Pubitemid 30198109)
7. Considine RV, Sinha MK, Heiman ML, Kriauciunas A, Stephens TW, Nyce MR, Ohannesian JP, Marco CC, McKee LJ, Bauer TL, Caro JF (1996) Serum immunoreactive-leptin concentrations in normal-weight and obese humans. N Engl J Med 334:292-295 (Pubitemid 26033933)
8. Deeb SS, Fajas L, Nemoto M, Pihlajamaki J, Mykkanen L, Kuusisto J, Laakso M, Fujimoto W, Auwerx J (1998) A Pro12Ala substitution in PPARgamma2 associated with decreased receptor activity, lower body mass index and improved insulin sensitivity. Nat Genet 20:284-287 (Pubitemid 28507675)
9. Evans M, Brown J, McIntosh M (2002a) Isomer-specific effects of conjugated linoleic acid (CLA) on adiposity and lipid metabolism. J Nutr Biochem 13:508
10. Evans ME, Brown JM, McIntosh MK (2002b) Isomer-specific effects of conjugated linoleic acid (CLA) on adiposity and lipid metabolism. J Nutr Biochem 13:508-516 (Pubitemid 35286669)
11. Fajas L, Auboeuf D, Raspe E, Schoonjans K, Lefebvre A-M, Saladin R, Najib J, Laville M, Fruchart J-C, Deeb S, Vidal-Puig A, Flier J, Briggs MR, Staels B, Vidal H, Auwerx J (1997) The organization, promoter analysis, and expression of the human PPARgamma gene. J Biol Chem 272:18779-18789 (Pubitemid 27318225)
12. Fisher E, Boeing H, Fritsche A, Doering F, Joost HG, Schulze MB (2009) Whole-grain consumption and transcription factor-7-like 2 (TCF7L2) rs7903146: Gene-diet interaction in modulating type 2 diabetes risk. Br J Nutr 101:478-481
13. Fritsche J, Steinhart H (1998) Amounts of conjugated linoleic acid (CLA) in German foods and evaluation of daily intake. Zeitschrift fur Lebensmitteluntersuchung und-Forschung A 206:77-82 (Pubitemid 128763303)
14. Gomez P, Perez-Martinez P, Marin C, Camargo A, Yubero-Serrano EM, Garcia-Rios A, Rodriguez F, Delgado-Lista J, Perez-Jimenez F, Lopez-Miranda J (2010) APOA1 and APOA4 gene polymorphisms influence the effects of dietary fat on LDL particle size and oxidation in healthy young adults. J Nutr 140:773-778
15. Helwig U, Rubin D, Kiosz J, Schreiber S, Folsch UR, Nothnagel M, Doring F, Schrezenmeir J (2007) The minor allele of the PPARgamma2 pro12Ala polymorphism is associated with lower postprandial TAG and insulin levels in non-obese healthy men. Br J Nutr 97:847-854 (Pubitemid 46554399)
16. Iwaki M, Matsuda M, Maeda N, Funahashi T, Matsuzawa Y, Makishima M, Shimomura I (2003) Induction of adiponectin, a fat-derived antidiabetic and antiatherogenic factor, by nuclear receptors. Diabetes 52:1655-1663 (Pubitemid 36792453)
17. Kallen CB, Lazar MA (1996) Antidiabetic thiazolidinediones inhibit leptin (ob) gene expression in 3T3-L1 adipocytes. Proc Natl Acad Sci USA 93:5793-5796 (Pubitemid 26191315)
18. Kennedy A, Overman A, LaPoint K, Hopkins R, West T, Chuang C-C, Martinez K, Bell D, McIntosh MK (2008) Conjugated linoleic acid-mediated inflammation and insulin resistance in human adipocytes are attenuated by resveratrol. J Lipid Res 50(2):225-232
19. Lonnqvist F, Arner P, Nordfors L, Schalling M (1995) Overexpression of the obese (ob) gene in adipose tissue of human obese subjects. Nat Med 1:950-953
20. Medina EA, Horn WF, Keim NL, Havel PJ, Benito P, Kelley DS, Nelson GJ, Erickson KL (2000) Conjugated linoleic acid supplementation in humans: Effects on circulating leptin concentrations and appetite. Lipids 35:783-788 (Pubitemid 30624544)
21. Park Y, Albright KJ, Liu W (1997) Effect of conjugated linoleic acid on body composition in mice. Lipids 32:853-858 (Pubitemid 27360392)
22. Poirier H, Shapiro JS, Kim RJ, Lazar MA (2006) Nutritional supplementation with trans-10, cis-12-conjugated linoleic acid induces inflammation of white adipose tissue. Diabetes 55:1634-1641. doi:10.2337/db06-0036 (Pubitemid 44324115)
23. Reseland JE, Haugen F, Hollung K, Solvoll K, Halvorsen B, Brude IR, Nenseter MS, Christiansen EN, Drevon CA (2001) Reduction of leptin gene expression by dietary polyunsaturated fatty acids. J Lipid Res 42:743-750 (Pubitemid 32509598)
24. Riserus U, Arner P, Brismar K, Vessby B (2002) Treatment with dietary trans10cis12 conjugated linoleic acid causes isomerspecific insulin resistance in obese men with the metabolic syndrome. Diabetes Care 25:1516-1521 (Pubitemid 41071104)
25. Roche HM (2005) Fatty acids and the metabolic syndrome. Proc Nutr Soc 64:23-29 (Pubitemid 40685748)
26. Rubin D, Helwig U, Nothnagel M, Folsch UR, Schreiber S, Schrezenmeir J (2010) Association of postprandial and fasting triglycerides with traits of the metabolic syndrome in the metabolic intervention cohort kiel. Eur J Endocrinol 162:719-727
27. Ryder JW, Portocarrero CP, Song XM, Cui L, Yu M, Combatsiaris T, Galuska D, Bauman DE, Barbano DM, Charron MJ, Zierath JR, Houseknecht KL (2001) Isomer-specific antidiabetic properties of conjugated linoleic acid: Improved glucose tolerance, skeletal muscle insulin action, and UCP-2 gene expression. Diabetes 50:1149-1157 (Pubitemid 32374547)
28. Simon I, Vendrell J, Gutierrez C, Fernandez-Real JM, Vendrell I, Gallart L, Fontova R, Richart C (2002) Pro12Ala substitution in the peroxisome proliferator-activated receptor-gamma is associated with increased leptin levels in women with type-2 diabetes mellitus. Horm Res 58:143-149
29. Takata N, Awata T, Inukai K, Watanabe M, Ohkubo T, Kurihara S, Inaba M, Katayama S (2004) Pro12Ala substitution in peroxisome proliferator-activated receptor[gamma]2 is associated with low adiponectin concentrations in young Japanese men. Metabolism 53:1548
30. Tan GD, Neville MJ, Liverani E, Humphreys SM, Currie JM, Dennis L, Fielding BA, Karpe F (2006) The in vivo effects of the Pro12Ala PPARgamma2 polymorphism on adipose tissue NEFA metabolism: The first use of the Oxford Biobank. Diabetologia 49:158-168 (Pubitemid 43151627)
31. Thamer C, Machicao F, Fritsche A, Stumvoll M, Haring H (2003) No influence of the PPAR[gamma]2 Pro12Ala genotype on serum adiponectin concentrations in healthy Europeans. Metabolism 52:798
32. Tonjes A, Scholz M, Loeffler M, Stumvoll M (2006) Association of Pro12Ala polymorphism in peroxisome proliferator-activated receptor gamma with Pre-diabetic phenotypes: Meta-analysis of 57 studies on nondiabetic individuals. Diabetes Care 29:2489-2497 (Pubitemid 44912258)
33. Whigham LD, Watras AC, Schoeller DA (2007) Efficacy of conjugated linoleic acid for reducing fat mass: A meta-analysis in humans. Am J Clin Nutr 85:1203-1211 (Pubitemid 46740460)
34. Yamamoto Y, Hirose H, Miyashita K, Nishikai K, Saito I, Taniyama M, Tomita M, Saruta T (2002) PPAR[gamma]2 gene Pro12Ala polymorphism may influence serum level of an adipocytederived protein, adiponectin, in the Japanese population. Metabolism 51:1407